1-10 of 83 results
Applying for a patent term extension in Australia? The formulation for success has changed
On 1 December 2025, the Federal Court of Australia exercising its appellate jurisdiction (the Full Court) handed down a bombshell decision: while patents for new active pharmaceutical ingred ...
PE Horizons 2025: the year to get creative
Key PE trends from 2024 and what these mean for the Australian and global markets in 2025. ...
Five things to know about investment in healthtech
The use of technology to improve or create efficiencies in the delivery of healthcare services, and to progress precision/preventative models is continuing to drive investment in Healthtech. Here are our 'top 5' tips for investing in Healthtech. ...
Cyber resilience and incident response in healthcare
Cyber incidents are disproportionately frequent in the healthcare sector—and their consequences are often more severe. The potentially life-threatening risk to patient care means that healthcare ...
Allens advises on acquisition financing of the Jones Radiology business
Allens advised the Commonwealth Bank of Australia (CBA) – the sole funder on the transaction – which involved the acquisition of a 49% shareholding previously held by I-MED Radiology. Jones ...
Allens advises BDT & MSD on $1.6bn investment in DBG Health
The deal includes a potential follow-on investment of up to $1 billion, representing one of the largest private, founder-led transactions in Australia. Allens collaborated with Sidley Austin in New ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
Competition news
In Touch looks at what's been happening in Competition this month and what it means for your business ...
ACCC's Enforcement and Compliance priorities for 2017
Criminal cartels unfair contract terms consumer guarantees and the health construction and agriculture sectors are some of the ACCCs key enforcement and compliance priorities for 2017 ACCC Chairman Rod Sims released the ACCCs 2017 Compliance and Enforcement Policy on Friday 24 February 2017 ...
Costs before Caution - Australia's unique approach to the interchangeability of biosimilars
Recent developments in Australia suggest that there has been a deliberate prioritisation of the cost benefits of facilitating biosimilar interchangeability over the safety and efficacy risks that can arise when biosimilars are used interchangeably ...